2 Dec 2020 16:25
Concepta PLC
("Concepta" or the "Company")
Change of name to MyHealthChecked Plc
Concepta PLC (AIM: CPT), the personalised healthcare company, confirms that it has today received confirmation from Companies House that its name has been changed and formally registered as MyHealthChecked Plc.
The Company expects that trading in the Company's shares under the new name will commence on 3 December 2020. The Company's ticker symbol will change to MHC. The Company's website can now be found at www.myhealthcheckedplc.com.
Shareholdings will be unaffected by the change of name and existing share certificates should be retained as they will remain valid for all purposes. Any new share certificates issued will bear the name MyHealthChecked Plc.
Concepta plc | www.conceptaplc.com |
Penny McCormick, Chief Executive Officer | via Walbrook PR |
Maddy Kennedy, Chief Financial Officer | |
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin | |
Novum Securities (Joint Broker) | Tel: +44 (0)20 7399 9400 |
Colin Rowbury | |
Oberon Capital Ltd (Joint Broker) | Tel: +44 (0)203 179 5344 |
Mike Seabrook | mikeseabrook@oberoninvestments.com |
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com |
Paul McManus | Mob: +44(0)7980 541 893 |
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company with two diverse, customer-facing at-home testing brands in its portfolio:
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the recent acquisition of The Genome Store. The tests will be made available on line, and would be viable for over the counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
Mylo targets the personalized mobile health market, with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant, and providing insight to unexplained infertility. myLotus range of IVDs are CE-marked and are expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.
myLotus range of IVDs are currently the UK's only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin ("hCG") hormone level during pregnancy.